September 2019 Thematic brief on Antimicrobial Resistance Multisectoral action to tackle antimicrobial resistance Synergy between sectors: controlling antimicrobial resistance through joint government actions Antimicrobial agents are used to treat infectious diseases caused by micro- organisms such as bacteria, viruses or fungi. Antibiotics are medicine used to treat people and animals for bacterial diseases. The development of anti- biotics is among the most important achievements of medical science. This medicine can cure dangerous diseas- es such as pneumonia or septicaemia that often proved fatal in the past. Antimicrobial resistance is the ability of microorganisms to resist antimicrobial agents. Especially concerning is the global rise in bacteria that can resist the effect of common antibiotics.Antibi- otic resistance means bacteria becom- ing less sensitive and, in some cases, entirely insensitive to antibiotics, so that treating people for common and serious infections becomes difficult or impossible. The development of resistance is a natural adaptation mechanism in mi- croorganisms such as bacteria. Resist- ant bacterial strains are present every- where in the environment. However, the excessive and inappropriate use of antibiotics, such as using them to treat viral conditions or as growth promoters in animal husbandry, accelerates the development of resistance. Poor infec- tion control practices and the spread of resistant organisms connected to global trade have transformed antibi- otic resistance into a serious threat to public health worldwide. The problem of increasing antimicrobi- al resistance affects human medicine, veterinary medicine, agriculture, food safety and the environment. Only cross-cutting involvement of diverse stakeholders across sectors and levels of organization and governance in accordance with the One Health approach has a chance of succeed- ing, which is in line with the goal and approaches of Health 2020. The main policies shaping efforts and priorities in the WHO European Region are the Global Action Plan on Antimicrobial Resistance, endorsed by WHO, the Food and Agriculture Organization of the United Nations and World Organisation for Animal Health in May 2015 and the European strate- gic action plan on antibiotic resistance adopted by European Member States in September 2011. Key messages The goal of Health 2020 is to significantly improve the health and well-being of populations, reduce health inequalities, strengthen public health and ensure people-centred health systems that are universal, equitable, sustainable and of high quality. 1 2 34 5 Health and well-being are best achieved if the whole of govern- ment works together and Health 2020 promotes whole-of-govern- ment and whole-of-society ap- proaches. Health and well-being can be improved and health inequali- ties reduced through appropriate policies and working with other sectors. Different countries, cities and communities have different starting-points: each is unique and can pursue common goals through different pathways. Social progress is best meas- ured by objective indicators of health, health equity and well-being, and this includes the conditions in which people are born, live and work. . HEALTH 2020 Health and well-being are public goods and assets for human development that contribute to strong, dynamic and creative societies. In the European Union (EU) and the European Economic Area in 2015 alone, an estimated 33 000 people died as a result of infections that cannot be treated with antimicrobial agents. Infections caused by these selected multidrug-resistant bacteria in the EU result in extra health-care costs and productivity losses of at least €1.5 billion each year. According to Stemming the superbug tide: just a few dollars more, southern Europe risks being especially severely affected. Italy, Greece and Portugal are forecast to top the list of Organisation for Economic Co- operation and Development (OECD) countries with the highest mortality rates from antimicrobial resistance. The resistance proportions for eight high-priority combinations of antibiotics and bacteria increased from 14% in 2005 to 17% in 2015 across OECD countries, but countries differed great- ly. The average resistance proportions in Greece, the Republic of Korea and Turkey (about 35%) were seven times higher than in Iceland, Netherlands and Norway, the countries with the lowest proportions (about 5%). The average resistance growth seems to be slowing down, but the report emphasizes serious causes for concern. Across the OECD, resistance to second- and third-line antibiotics – the most advanced and effective line of defence to prevent infections – is expected to be 70% higher in 2030 compared with 2005 for the same combinations of antibiotics and bacteria, and resistance to third-line treatments will double in EU countries. Surveillance provides a basis for taking action to control AMR and to estimate the health and economic burden. WHO/Europe together with partners established the Central Asian and Eastern European Surveillance of Antimicrobial Resistance (CAESAR) network. It is one of many activities to support Member States in their efforts to tackle AMR. Setting the scene: antimicrobial resistance and health in the WHO European Region 17% increase increase across the OECD in resistance proportions for eight high-priority combinations of antibiotics and bacteria 33K people died across the EU and EEA as a result of infections that connot be treated with antimicrobial agents (2017) 70% higher line of defence to prevent infections in 2030 compared to 2005 across the OECD 1.5b extra health-care costs and productivity losses of at least €1.5 billion each year in the EU and EEA 3 All Member States of the WHO European Region have agreed to monitor progress against six common targets: What makes societies prosper and flourish can also make people healthy: policies that recognize this have more impact. Building awareness and capacity to make health objectives part of society’s overall socioeconomic and human development is essential. All policy fields, including health, need to reform their ways of working and use new forms and approaches to policy at the global, national and local levels. Reduce premature mortality in the European Region by 2020 Increase life expectancy in the European Region Reduce health inequalities in the European Region Enhance the well-being of the European Region population Ensure universal health coverage and the right to the highest attainable level of health Set national goals and targets related to health in Member States Health 2020: a framework for action The goal of Health 2020 is to significantly improve the health and well-being of populations, reduce health inequalities, strengthen public health and ensure people-centred health systems that are universal, equitable, sustainable and of high quality. 1. 2. 3. 4. 5. 6. The Sustainable Development Goals All 193 Member States of the United Nations adopted the United Nations 2030 Agenda for Sustainable Development at the United Nations Sustainable Development Summit in 2015. The 17 Sustainable Development Goals are a universal call to action to end poverty, protect the planet and ensure that all people enjoy peace and prosperity. They build on the successes of the Millennium Development Goals while including new areas such as climate change, economic inequality, innovation, sustainable consumption and peace and justice. The Goals are interconnected and require multisectoral and intersectoral action – the key to success for any one Goal involves tackling issues more commonly associated with another. Although AMR is not specifically refered to in any of the SDGs, the achievement of many of these is conditional upon addressing AMR effectively (e.g. SDGs 2, 3, 6, and 17). Multisectoral determinants of antimicrobial resistance Antimicrobial resistance is a growing threat to global health. First, many of the same microbes (such as bacteria, viruses, fungi and parasites) affect both animals and humans through the environment they share, and 60% of all human diseases originate in animals. This means that, when microbes develop drug resistance in animals, they can easily go on to affect humans, creating difficulty in treating the people who have these diseases and infections. Second, the same classes of antimicrobial agents are often used for both humans and food-producing animals. Third, the food chain is an important route for transmitting disease. This indicates that no single sector has the capacity to solve the growing problem of antimicrobial resistance alone and that collective action is needed to make progress. The One Health approach means coordinating action across sectors – such as public health, veterinary medicine and environment health – to achieve the best possible health outcomes for all. Cross-cutting aspects • Equitable access to medicines • Education and awareness • Investment and financial aspects • Drug regulatory issues • Links between biology and gender Surveillance, monitoring and evidence • Surveillance systems • Laboratory capacity • Data infrastructure and • systematic data collection Prevention • Preventing and controlling infection • Vaccination Prudent use of antimicrobial agents • Antimicrobial stewardship programmes • Phasing out antibiotic growth promoters Resistance control and transmission • Introduction of antimicrobial resistance (hospitals, herds, flocks) • Environmental spread • Spread via the food chain Research and development • New antimicrobial agents, rapid diagnostic tests and new vaccines • Knowledge about the sources, transmission and trends of antimi- crobial resistance 5 Fig. 1: Joint actions across sectors to address antim icrobial resistance Intersectoral policies and interventions to address the determinants of antimicrobial resistance As reflected in Fig. 1, given the diversity of government actors involved in combating antimicrobial resistance, interventions within and outside the health sector are needed to address the underlying determinants of health. The following charts include examples of adequate joint actions throughout the different phases to improve the situation regarding antimicrobial resistance. Surveillance systems Veterinary sector, food safety, agricultural sector, environmental sector, reference laboratories, health-care facilities, pharmacies, universities Developing and implementing a comprehensive monitoring system for antimicrobial resistance and antibiotic consumption Publishing a joint report regularly CHALLENGES IN RELATION TO: MAIN SECTORS INVOLVED JOINT ACTIONS TO IMPROVE ANTIMICROBIAL RESISTANCE Surveillance, monitoring and evidence Laboratory capacity Veterinary sector, laboratories, universities Developing and expanding network of reference laboratories for investigating antimicrobial resistance and ensuring quality assurance in all laboratories Drawing up national guidelines for the attention of the laboratories, which should have the capacity to implement these guidelines Data infrastructure and systematic data Veterinary sector, food safety, agricultural sector, environmental sector, reference laboratories Gathering and analysing data systematically and using this information for surveillance purposes Ensuring national and international comparability, as well as between sectors CHALLENGES MAIN SECTORS INVOLVED JOINT ACTIONS TO IMPROVE ANTIMICROBIAL RESISTANCE Preventing and controlling infection in human and veterinary medicine Veterinary and agricultural sector, food safety, economic sector Strengthening International Health Regulations capacity and implementing legislation to institutionalize and strengthen the role of International Health Regulations capacity and operations Implementing evidence-informed guidelines on core components of preventing and controlling infection in human and veterinary medicine Implementing good clinical practice and higher biosecurity and improving husbandry and animal health Advising livestock farmers in systematic and continual herd management, intensifying cooperation between farmers and veterinarians Prevention Vaccination rates Veterinary and agricultural sector, food processing sector Supporting vaccination campaigns aimed at specific target groups and diseases Level of antimicrobial stewardship in human and veterinary medicine and in agriculture Veterinary and agricultural sector, food safety, economic sector Following the WHO list of critically important antimicrobial agents; restricting the use of non-therapeutic antimicrobial agents and antimicrobial agents that are critically important for human use. Developing and reviewing guidelines on prescribing, dispensing and using antimicrobial agents and ensuring their implementation Adopting antimicrobial stewardship programmes Enhancing the basic and further training of doctors, veterinarians and animal owners Enhancing the basic and further training of doctors, veterinarians and animal owners CHALLENGES MAIN SECTORS INVOLVED JOINT ACTIONS TO IMPROVE ANTIMICROBIAL RESISTANCE Prudent use of antimicrobial agents CHALLENGES MAIN SECTORS INVOLVED JOINT ACTIONS TO IMPROVE ANTIMICROBIAL RESISTANCE Introduction of antimicrobial resistance into health-care facilities and animal herds, taking into account international trade and travel activities Veterinary and agricultural sector Preventing the entry of resistance into health-care facilities and animal herds and flocks and its subsequent spread through entry screening, hygiene and biosafety measures Resistance control and transmission Environmental spread Agricultural sector, environmental sector, academic research Reducing the volume of antimicrobial agents, resistance genes and resistant bacteria entering the environment, such as from hospitals, animal husbandry, agriculture as well as research and production facilities Setting out basic principles for the entry of antimicrobial agents into farmyard manure, soil and water and their persistence and activity Monitoring and regulating the environment and environmentally related activities or products that influence the spread and development of antimicrobial resistant pathogens Increasing wastewater treatment and water, sanitation and health (WASH) activities Spread of antimicrobial resistance through the food chain Veterinary and agricultural sector, food-processing sector, consumer associations Developing hygiene and decontamination measures 7 Lack of new antimicrobial agents Veterinary sector, pharmaceutical industry, economic and financial sector, academic research Discovering novel antimicrobial molecules to improve the treatment of humans and animals Coordinating research and development by using such institutions as the Joint Programming Initiative on Antimicrobial Resistance, Global Antibiotic Research and Development Partnership, CARB-X, Global Antimicrobial Resistance Research and Development Hub and International Centre for Antimicrobial Resistance Solutions. Following WHO’s global priority list of antibiotic-resistant bacteria to guide research on, discovery of and development of new antibiotics Considering incentives for the pharmaceutical industry such as pull-and-push incentives and market entry rewards CHALLENGES MAIN SECTORS INVOLVED JOINT ACTIONS TO IMPROVE ANTIMICROBIAL RESISTANCE Research and development Lack of new rapid diagnostic tests to distinguish between bacterial and viral infections in human and veterinary medicine Veterinary sector, economic and financial sector, pharmaceutical industry, academic research Developing rapid diagnostic techniques to improve the treatment of humans and animals Considering incentives to develop a simple rapid test Lack of new vaccines and availability of new vaccines Veterinary sector, pharmaceutical industry, academic research Stimulating research on and the use of vaccines CHALLENGES MAIN SECTORS INVOLVED JOINT ACTIONS TO IMPROVE ANTIMICROBIAL RESISTANCE Equitable access to medicines Economic sector, veterinary and agricultural sector, food processing sector Strengthening efforts towards universal health coverage Availability of first-choice antibiotics and vaccines Cross-cutting aspects Education and awareness Educational sector, veterinary sector, mass media, NGOs, consumer associations Informing human and veterinary health professionals and the general public about antibiotic resistance and how it can be prevented (such as improving kitchen hygiene) Knowledge about the dissemination and the sources of antimicrobial resistance Academic research, veterinary and agricultural sector, environmental sector Increasing knowledge about how resistance develops and is transmitted to interrupt these processes Investment, financial aspects Financial and economic sector, foundations Budgeting and providing the necessary resources 8 Drug regulatory issues Medical associations, veterinary sector, economic sector, law enforcement authorities, drug regulatory agencies, pharmaceutical industry, pharmacist associations Regulating the availability of antibiotics without prescription and banning over-the-counter sale of antimicrobial agents, counterfeit drugs and informal markets Prohibiting the use of antibiotics as growth promoters in livestock Identifying and modifying market mechanisms and incentive systems such as the promotional activities of the pharmaceutical industry Strengthening drug regulatory agencies to ensure the quality of antibiotics on the market CHALLENGES MAIN SECTORS INVOLVED JOINT ACTIONS TO IMPROVE ANTIMICROBIAL RESISTANCE Cross-cutting aspects 9 Reducing health inequalities: to reduce health inequalities, the following should be addressed. LIFE-COURSE STAGE • Social protection for women, mothers- to-be and young families • Universal, high-quality and affordable early-years education and care system • Eradication of unsafe work and access to employment and high-quality work • Coherent and effective intersectoral action to tackle inequalities at older ages WIDER SOCIETY • Improved social protection, according to need • Co-creation and partnership with those targeted, civil society and civic partners • Action to reduce social exclusion • Gender equity approachh BROADER CONTEXT • Promoting equity through tax and transfer payments • Long-term planning through links with other policies SYSTEMS • Greater coherence across sectors • Comprehensive responses • Regular reporting and public scrutiny Intersectoral response to other key challenges beyond antimicrobial resistance Antibiotics are used too often and incorrectly today. Nevertheless, the opposite also happens: there have been recent repeated shortages in the supply of antibiotics. A shortage of antibiotics occurs because the active ingredients for an antibiotic are usually produced in just a few factories. This means that a single manufacturing failure can have major effects. The fragile supply of antibiotics receives little attention on the global political stage. Further, many low- and middle- income countries face the challenge of antibiotics from unofficial routes, black markets and counterfeit drugs. In addition, the pharmaceutical industry has little incentive to invest in research for developing new classes of antibiotics. Research and development are risky and expensive, antibiotics have low profit margins and demand growth comes mainly from lower-income countries. Between 2000 and 2015, global demand for antibiotics increased by 65%. Four of the six countries with the highest antibiotic consumption rates were low- and middle-income countries. This challenge requires public investment in developing medicine, but this is difficult to justify if the profits from resulting sales are purely private. Cross-cutting aspects To reduce health inequalities and achieve health for all, the joint policies and interventions mentioned above must be performed with full respect for the principle of non-discrimination and, overall, following a human rights approach. All countries must combat antimi- crobial resistance, even if all are not equally affected by the problem. Abuse or overuse of antibiotics in just a few regions of the world is enough to over- turn the achievements in containing antimicrobial resistance everywhere. Antimicrobial resistance strikes poor people the hardest. Lack of access to water and sanitation and to affordable and effective antibiotics significantly affects women and children in low-in- come countries and poorer people in middle- and high-income countries. Gender is also a determining factor in exposure to infection and disease, making the treatment of men and women, and links between biological differences and gender, norms, roles, and inequalities, important consid- erations in combating antimicrobial resistance. Childbirth, abortion and health care all expose women to a greater range of infection, making antimicrobial resistance an especially important consideration in the health care of mothers. In addition, female dominated professions are also asso- ciated with more frequent exposure to infection and disease such as teaching, and in particular health- care where women comprise 67% of frontline workers, giving them greater risk of infection, some of which may be with resistant pathogens. Most current health-care systems in many countries were developed assuming the unlimited availability of effective and affordable antimicrobial agents. Existing health-care systems should therefore be updated to miti- gate antimicrobial resistance. In this sense, the efforts towards universal health coverage are very effective. HEALTH 2020 10 The right to health and sector mandates for multisectoral and intersectoral action for health and well-being Resourcing organization for multisectoral and intersectoral action for health and well-being The capacity of institutions and individuals for designing, implementing and delivering multisectoral and intersectoral action for health and well-being 2030 Agenda for Sustainable Development: a political mandate and transformative call for action 1. 2. 3. Achieving the Sustainable Development Goals (SDGs) requires working in a transformative way in order to implement a set of coherent, evidence-informed policies that address health, well-being and all their determinants throughout the life course and across all sectors of government and society. Revitalized global and regional partnerships are essential, and will provide the support and momentum to this societal and global effort. Transformative governance for action on antimicrobial resistance The adoption of the Health 2020 health policy framework for the WHO European Region in 2012 by all European Member States, with governance for health as a twin strategic objective alongside improved health equity, marked an invigorated strategic approach in the Region to strengthen governance for health and intersectoral action. This provides an excellent foundation for operationalizing and implementing the 2030 Agenda and the Sustainable Development Goals, which requires good governance, new models of partnership and scaling up intersectoral work as the means to achieve global, regional and national goals and targets and to meet today’s complex global challenges, including antimicrobial resistance. Moving towards models of governance that deliver through their design health, equity and well-being is an example of the transformative response called for by the 2030 Agenda. Involving, managing, coordinating, developing accountability and coherence and supporting the implementation of action between diverse actors across all levels of government and beyond is necessary to achieve global, regional and national goals and targets and to effectively address today’s complex global challenges. The transformative approach to improved governance is facilitated through whole-systems approaches at each individual level and node within a system (whole of government, whole of society, whole of city and whole of school) that engage all levels of governance within a system, from the international through the national and the regional to the local, of which the One Health approach to address antimicrobial resistance is a clear example. Capacity for intersectoral governance for health and well-being depends on three key factors: SDGs for tackling AMR For further information, see the Con- cept note: assessment tool for govern- ance for health and well- being.
Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages 3.D Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks. 3.3 End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases 3.2 By 2030, end preventable deaths of newborns and children under 5 years of age 3.8 Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all Sustainable Development Goal 8: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all 8.1 Sustain per capita economic growth in accordance with national circumstances and, in particular, at least 7 per cent gross domestic product growth per annum in the least developed countries GOAL SUSTAINABLE DEVELOPMENT GOAL TARGET Sustainable Development Goal targets for tackling antimicrobial resistance Sustainable Development Goal 6: Clean water and sanitation 6.1 By 2030, achieve universal and equitable access to safe and affordable drinking water for all 6.3 By 2030, improve water quality by reducing pollution, eliminating dumping and minimizing release of hazardous chemicals and materials, halving the proportion of untreated wastewater and substantially increasing recycling and safe reuse globally Sustainable Development Goal 2: End hunger, achieve food security and improved nutrition and promote sustainable agriculture Combined with Sustainable Development Goal 13 to “Take urgent action to combat climate change and its impacts”, food security and climate change are greatly affected by antibiotic use in the human food system, agriculture, and aquaculture. Sustainable Development Goal 17: Strengthen the means of implementation and revitalize the Global Partnership for Sustainable Development 17.9 Enhance international support for implementing effective and targeted capacity-building in developing countries to support national plans to implement all the sustainable development goals, including through North–South, South–South and triangular cooperation 13 The WHO Regional Office for Europe The World Health Organization (WHO) is a specialized agency of the United Nations created in 1948 with the primary responsibility for international health matters and public health. The WHO Regional Office for Europe is one of six regional offices throughout the world, each with its own programme geared to the particular health conditions of the countries it serves. Member States Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia and Herzegovina Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands North Macedonia Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan Turkey Turkmenistan Ukraine United Kingdom Uzbekistan Original: English URL: www.euro.who.int © World Health Organization 2019. All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. World Health Organization Regional Office for Europe UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark Tel.: +45 45 33 70 00 Fax: +45 45 33 70 01 E-mail: eupcrgov@who.int This brief has been produced as part of the Multi- and Intersectoral brief series by the Governance for Health Programme, Division of Policy and Governance for Health and Well-being, in collaboration with the Control of AMR Programme, Division of Health Emergencies and Communicable Diseases, both WHO Regional Office for Europe. For more, please see this link